Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 331.15B |
| Revenue (ttm) | 82.47B |
| Net Income (ttm) | 20.13B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 16.45 |
| Forward PE | n/a |
| Dividend | 4.62 (3.38%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 4,446 |
| Average Volume | 7,752 |
| Open | 139.76 |
| Previous Close | 137.80 |
| Day's Range | 136.24 - 139.76 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | 0.48 |
| RSI | 39.64 |
| Earnings Date | Apr 15, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Dividend Kings Down Today: Why Johnson & Johnson (JNJ), Coca-Cola (KO) and Procter & Gamble (PG) Are Sliding
Markets are moving higher for the second straight day. All thanks to talk of cooling trade war tensions, and President Trump’s admission that he has no plans to fire Federal Reserve Chief Jerome Powel...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Two Stocks To Consider During Market Unrest To Provide Income Stability
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...
JNJ says new data buoys TAR-200 monotherapy for bladder cancer
Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
IBM, Parker-Hannifin Among 10 Companies To Announce Dividend Increases In Second Half Of April
Discover upcoming dividend increases from companies like Procter & Gamble, Johnson & Johnson, Ameriprise Financial, and Parker-Hannifin.
Johnson & Johnson (JNJ) Sees Growth Amid Trade Tensions
Johnson & Johnson (JNJ) Sees Growth Amid Trade Tensions
Johnson & Johnson: 15% of AI Use Cases Deliver 80% of Value
Johnson & Johnson reportedly found that 10% to 15% of artificial intelligence use cases deliver 80% of the value.
Johnson & Johnson Pivots Its AI Strategy
The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.
Energy stocks surge as healthcare giants make strides
Energy stocks surge as healthcare giants make strides Today’s market heatmap reveals a marked shift as energy stocks gain significant traction, while healthcare giants make noteworthy advances. Invest...
Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends
Most high-yield strategies are ticking time bombs. Don't get wiped out when the next downturn hits. Discover the only portfolio blend that can deliver sustainable and rising dividends through inflatio...
Netflix stock has been nearly unscathed by Trump tariffs. Some think it could be Silicon Valley’s version of Johnson & Johnson
As recession fears mount on Wall Street, management is still reportedly setting ambitious long-term goals.
4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Ti...
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a...
Healthy Returns: What drugmakers are saying about Trumps looming pharmaceutical tariffs
What Johnson & Johnson and Eli Lilly are saying about Trumps pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
These three stocks in the news on Tuesday have trading potential, Jeff Kilburg says
Jeff Kilburg, founder and CEO of KKM Financial, discussed Netflix, Johnson & Johnson and Under Armour on CNBC's "Power Lunch."
3-Stock Lunch: Netflix, Johnson & Johnson and Under Armour
Jeff Kilburg, KKM Financial co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+
The acquisitions of Alexandria Real Estate and Unilever enhance sector and geographical diversification, increase dividend income capacity, and reduce portfolio volatility, aligning with The Dividend ...
Johnson & Johnson boss warns tariffs could trigger a shortage of medicines as markets steady
The global head of drugs giant Johnson & Johnson has warned that US tariffs on the pharmaceutical industry could lead to medicines shortages.
Johnson & Johnson projects $400M tariff impact in 2025
Johnson & Johnson tops Wall Street expectations in Q1
Johnson & Johnson (JNJ) reported stronger-than-expected earnings. Goldman Sachs Global Investment Research head of the healthcare business unit Asad Haider joins Catalysts with Madison Mills and Stone...
Johnson & Johnson warns pharma tariffs could cause drug shortages
Medical devices like group’s surgical robots have already been hit by the new US charges